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Abstract: Pharmaceutical crops is an ambiguous term used by biologists and chemists for different categories of plants. 
This review focuses on the definition and scope of pharmaceutical crops. We define pharmaceutical crops as those culti-
vated species that are used for extraction or preparation of therapeutic substances such as active pharmaceutical ingredi-
ents (APIs), excipients used in pharmaceutical formulations, vaccines and antibodies, as well as other therapeutic proteins. 
Based on the type of pharmaceutical product, these crops can be classified into three distinct yet sometimes overlapping 
categories: crops for the production of small therapeutic molecules (STMs), large therapeutic molecules (LTMs), or stan-
dardized therapeutic extracts (STEs). This review briefly discusses the relationships of pharmaceutical crops with tradi-
tional food crops, medicinal plants, medicinal crops, and invasive species. It also addresses the importance, advantages, 
problems, and challenges of research and development of pharmaceutical crops.  
Keywords: Pharmaceutical crops, definition, active pharmaceutical ingredients, small therapeutic molecules, large therapeutic 
molecules, standardized therapeutic extracts, medicinal plants, medicinal crops. 
WHAT ARE PHARMACEUTICAL CROPS? 
Pharmaceutical crops is an ambiguous term used by sci-
entists of varying disciplines referring to different categories 
of plants and their utilization. Biologists often define phar-
maceutical crops as genetically modified (GM) or engi-
neered crops to produce vaccines, antibodies, and other 
therapeutic proteins [1-4], but sometimes, other terms for 
such a class of crops or practice are used. For example, 
pharma crops is used to designate transgenic plants for the 
production of pharmaceuticals (e.g., antibiotics, diagnostic 
compounds, antibodies, vaccines, etc.) or industrially-useful 
biomolecules (e.g., biodegradable plastics, engine oils, food 
processing enzymes, etc.), rather than for the production of 
food, feed or textile fibers [1]. Biopharming means a practice 
of using GM or engineered crops (e.g., tobacco, maize, soy-
beans, tomato, rice, wheat, potato, safflower, alfalfa, and leaf 
mustard) as bioreactors to produce large therapeutic mole-
cules [5]. However, natural product chemists occasionally 
use the term pharmaceutical crops for a different class of 
plants, those that produce pure small molecules as active  
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pharmaceutical ingredients, although there is not any clear 
definition [6, 7]. These pharmaceutical ingredients are natu-
rally-occurring single entities of secondary metabolites in 
plants. Well known examples for this chemical definition are 
Taxus spp. (Taxaceae) and Podophyllum spp. (Berberi-
daceae) for production of anti-cancer drugs, and Artemisia 
annua L. (Asteraceae) for an anti-malarial drug. The differ-
ent meanings of pharmaceutical crops as used by biologists 
and chemists may not only cause confusion in academia and 
industry, but also may often mislead the public.  
We define the term Pharmaceutical Crops as those culti-
vated species that are used for the extraction or preparation 
of therapeutic substances such as active pharmaceutical in-
gredients (APIs), excipients used in pharmaceutical formula-
tions, vaccines and antibodies, as well as other therapeutic 
proteins. Based on the type of pharmaceutical product, these 
crops can be classified into three distinct yet sometimes 
overlapping categories: crops for the production of small 
therapeutic molecules (STMs), large therapeutic molecules 
(LTMs), and standardized therapeutic extracts (STEs) (Table 
1). Pharmaceutical crops can be either terrestrial or aquatic 
species. Although marine organisms have shown promising 
potential in drug discovery [8-10], this review focuses on 
examples of terrestrial plants as pharmaceutical crops. It is 
estimated that there are 400-500 plant species currently man-
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aged as pharmaceutical crops for production of STMs, fewer 
species are used for production of LTMs, and thousands of 
species are managed as crops for STEs.  
Pharmaceutical Crops for the Production of Small 
Therapeutic Molecules (STMs) 
This group of pharmaceutical crops produces STMs 
(usually having a molecular weight of less than 1,000 
Daltons) as either APIs or their precursors. Typically, these 
small molecules are secondary metabolites. The plants pro-
ducing these STMs are often managed as new or potential 
crops via intact plant systems, tissue or cell culture systems. 
Some crops in this category are well known for the pro-
duction of promising active ingredients which are used di-
rectly or semi-synthetically modified as anti-cancer drugs. In 
the late 1960s, Dr. Monroe Wall, Dr. Mansukh Wani, and 
colleagues at the Research Triangle Institute isolated and 
characterized the anti-tumor pentacyclic alkaloid camptothe-
cin (CPT) (1) (Fig. 1) from the wood and bark of Camp-
totheca acuminata Decne. (Cornaceae) [11]. Because CPT 
(1) is insoluble in water, its water-soluble sodium salt was 
used in the initial clinical trials of the 1970s, but the results 
were not promising [12]. Interest in CPT drugs was not re-
kindled until its unique mechanism of action was discovered. 
In 1985, Hsiang et al. found that CPT traps the enzyme 
topoisomerase I (TOPI), in complex with DNA, thus pre-
venting cancer cell DNA replication and killing tumor cells 
[13]. From 1985 to 1995, extensive research efforts were 
focused on developing water-soluble and bioactive analogs 
of natural CPT (1) and 10-hydroxycamptothecin (HCPT) (2) 
(Fig. 1). In the mid-1990s, two CPT analogs, topotecan (Hy-
camtin®) (3) (Fig. 1) and irinotecan (trade names Campto-
sar® and Campto, also known as CPT-11) (4) (Fig. 1), re-
ceived the United States Food and Drug Administration 
(FDA) approvals and have been primarily used in patients 
with advanced ovarian and metastatic colorectal cancers, 
respectively. In the last decade, the global annual sales of the 
two CPT drugs totaled approximately $1 billion. The semi-
synthetic production of these two CPT drugs and several 
other CPT analogs for clinical trials requires CPT (1) or 
HCPT (2) as precursors.  
Camptotheca species (known by various common names 
including happytree, tree of life, cancer tree in English and xi 
shu in Chinese) are still a major source of CPT (1) and 
HCPT (2). The genus currently includes three species of de-
ciduous trees (C. acuminata, C. lowreyana S. Y. Li, and C. 
yunnanensis Dode) and its range is restricted to remote areas 
in southern China [14]. No wild trees of C. acuminata were 
identified in a 1994-1997 national survey of that nation, al-
though this species is commonly cultivated as an urban street 
tree in southern China. In 1997, it was listed as an endan-
gered species in China. Currently, fruits or leaves are har-
vested from cultivated C. acuminata trees along roads or 
small plantations for CPT (1) and HCPT (2) extraction. 
Camptotheca lowreyana and C. yunnanensis have small wild 
populations with tens of mature trees only in Guangdong and 
Yunnan provinces. Four high CPT-yielding cultivars of 
shrubs or trees were developed to harvest leaves and stems 
for sustainable production of CPTs: C. lowreyana ‘Katie’, 
‘CT168’, and ‘Hicksii’, and C. yunnanensis ‘Tropic’ [14, 
15]. A cultivation technique to enhance biosynthesis of CPTs 
in Camptotheca was developed [16].  
Table 1. Summary of Three Types of Pharmaceutical Crops 
Pharmaceutical Crops for the Production of  
Small Therapeutic Molecules 
(STMs) 
Large Therapeutic Molecules 
(LTMs) 
Standardized Therapeutic Extracts 
(STEs) 
Therapeutic Substances 
Molecule Type 
Molecular Weight 
 
Molecular Origin 
Purity  
In vitro Production 
 
Biotransformation 
Quality Control 
 
Basically secondary metabolites 
Low molecular weight (usually <1,000) 
 
Endogenous 
Pure 
Possible but most are not commercially 
feasible yet 
Possible and relatively easy 
Relatively easy 
 
 
Basically primary metabolites 
High molecular weight (usually 
10,000 to 100,000) 
Endogenous or exogenous 
Pure 
Possible but most are not commer-
cially feasible yet 
No data 
Relatively easy 
 
Both 
Usually of low molecular weight 
 
Endogenous 
Mixture 
May be unable to produce the same 
quality products 
No data 
Relatively difficult 
Crops 
Type 
 
Cultivation History 
 
Induction  
 
Traditional (possible Transgenic in the 
future)  
< 100 yrs 
 
Possible by stresses 
 
Traditional or Transgenic  
 
Non-transgenic crops: <100 yrs  
Transgenic crops:  <20 yrs 
No data 
 
Traditional 
 
Many cultivated for centuries 
 
Difficult to manage 
Ethnobotanic Uses Many are used in traditional medicines Transgenic crops are not used in 
traditional medicines 
Usually used in traditional medicines 
 
 
 
 
 
 
 
Fig. (1). Camptothecin (1) and 10-hydroxycamptothecin (2), two 
natural alkaloids isolated from Camptotheca spp. and their semi-
synthetic anti-cancer drugs topotecan (3) and irinotecan (4) (Camp-
totheca acuminata cultivated in Texas, USA, photo by S.Y. Li). 
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Taxus L. (yew) is another example of an important phar-
maceutical crop utilized for anti-cancer drug production. In 
the early 1970s, Wall, Wani, and co-workers isolated and 
elucidated the structure of the terpene paclitaxel (Taxol®) (5) 
(Fig. 2) from the bark of Pacific yew (Taxus brevifolia Peat-
tie) (Fig. 2), an evergreen and coniferous tree of the Tax-
aceae from the old-growth forests of the North American 
Pacific Northwest [17, 18]. The Pacific yew was long con-
sidered a “trash tree” [18]. Susan Horwitz demonstrated that 
paclitaxel’s unique antimitotic mechanism of action is to 
promote microtubule assembly and inhibit mitosis rather 
than preventing the formation of microtubules as with previ-
ous anti-cancer drugs [19, 20]. The unique structure and 
mode of action stimulated global interest in the drug’s de-
velopment. In the last two decades, paclitaxel (with various 
trade names including Taxol®, Onxal, Onxol®, Abraxane®, 
Apo-Paclitaxel®, Asotax, Bristaxol, Cryoxet, and Praxel) has 
been one of the most widely used chemotherapy agents in 
the world, particularly in patients with advanced and metas-
tatic ovarian and breast cancers. Docetaxel (Taxotere®) (6) 
(Fig. 2), a semi-synthetic analog is mainly used to treat non-
small cell lung cancer. Ortataxel (7) (Fig. 2), a third genera-
tion taxane is now in Phase II clinical trials against taxane-
resistant breast cancer [21].  
The early production of paclitaxel (5) relied on the bark 
of Pacific yew, with a limited supply of this nonrenewable 
source. The yield of paclitaxel (5) from the yew bark is tre-
mendously low; with 3,000 yew trees being needed to har-
vest enough bark to produce 1 kg of paclitaxel (5). Currently, 
paclitaxel (5), docetaxel (6), and ortataxel (7) can be pro-
duced by semi-synthesis using 10-deacetylbaccatin III (10-
DAB) (8) (Fig. 2) and other baccatins isolated from needles 
of European yew (T. baccata L.) and other yew species [22, 
23]. Over 400 taxanes have been isolated from various spe-
cies of Taxus [24]. Species cultivated for production of pacli-
taxel (5) since the 1990s include T. brevifolia in North 
America, T. baccata in Europe, T. wallichiana Zucc. (syn. T. 
yunnanensis W. C. Cheng & L. K. Fu), T. cuspidata Sieb. & 
Zucc. in China, and T. canadensis Marshall in Canada. In 
China, for example, 6672 hectares of Taxus plantations, in-
cluding the species T. madia (T. cuspidata × T. baccata), T. 
wallichiana, T. wallichiana var. chinensis (Pilger) Florin, 
and T. cuspidata, were located in 19 provinces in May 2005 
[25]. Although numerous companies supply Taxus seedlings, 
a high-yielding, fast growing cultivar is not yet available [25].  
Two other well-known pharmaceutical crops cultivated 
for anti-cancer drug production are Podophyllum L. 
(mayapple) and Catharanthus roseus (L.) G. Don 
(Madagascar periwinkle or rosy periwinkle). Podophyllum is 
a genus of six species of herbaceous perennial plants native 
to eastern Asia (five species) and eastern North America 
(one species). Eastern Asian P. emodi Wall. (syn. P. hexans-
drum Royle) and North American P. peltatum L. (Fig. 3) 
have long been used in traditional medicine. Toxic podo-
phyllin (a resin) from an ethanol extract of the rhizomes has 
been used to treat warts. In 1880, podophyllotoxin (9) (Fig. 
3), an aryltetrainlactone cyclolignan, was isolated from P. 
peltatum rhizomes [24]. Etoposide (10) (Fig. 3) and 
teniposide (11) (Fig. 3), two semi-synthetic analogs of podo-
phyllotoxin (9), are potent DNA TOPII cancer drugs used for 
small cell lung and testicular cancers and lympho-
mas/leukemias; likewise the water-soluble etoposide phos-
phate (also known as etopophos) (12) is used for refractory 
testicular cancer and small cell lung cancer (Fig. 3). At pre-
sent, both P. emodi and P. peltatum are cultivated for isola-
tion of podophyllotoxin (9) [26, 27]. Catharanthus roseus 
(also known as Vinca rosea L., family Apocynaceae) (Fig. 4) 
is an evergreen perennial species native and endemic to 
Madagascar, but now naturalized throughout the tropics and 
widely sold as a cultivated plant elsewhere. It is used for 
production of vinblastine (13) and vincristine (14) (Fig. 4), 
two well-known antimitotic cancer drugs used to treat Hodg-
kin’s lymphoma and acute childhood lymphoblastic leuke-
mia, respectively. Vinorelbine (Navelbine®) (15) and 
vindesine (Eldisine®) (16) (Fig. 4), two synthetic drugs de-
rived from vinca alkaloids, are used to treat non-small cell 
lung and advanced breast cancers, acute lymphoblastic leu-
kemia, and malignant melanoma [24].  
 
Fig. (3). Podophyllotoxin (9), a natural lignan isolated from 
Podophyllum spp., and semi-synthetic anti-cancer drugs etoposide 
(10), teniposide (11), and etoposide phosphate (12) (Podophyllum 
peltatum in Texas, USA: by S.Y. Li). 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Anti-cancer taxane drugs paclitaxel (5), docetaxel (6), and 
ortataxel (7) and their precursor 10-deacetylbaccatin III (8) isolated 
from Taxus spp. (Taxus brevifolia in the Pacific Northwest, USA: 
Courtesy of www.stevenfoster.com). 
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Active ingredients from several other pharmaceutical 
crops are currently being evaluated in cancer drug clinical 
trials, but severe side effects due to toxicity challenge drug 
development. For example, Cephalotaxus Sieb. & Zucc. 
(Cephaltaxaceae) native to southeastern Asia (including C. 
fortunei Hooker, C. sinensis (Rehder & E. H. Wilson) Li, C. 
oliveri Mast., C. mannii Hooker, and C. harringtonia 
(Forbes) K. Koch.) are used to isolate the anti-tumor agents 
harringtonine (17) and homoharringtonine (18) (Fig. 5), two 
alkaloids used as cancer drugs in China [28]. Homoharring- 
tonine (18) is being evaluated in clinical trials for treating 
myeloid leukemia in the United States, but has severe side 
effects [24]. Similarly, colchicine (19) isolated from 
Colchicum autumnale L. (Liliaceae) (Fig. 6) is used to treat 
gout and familial Mediterranean fever. The alkaloid and its 
natural analog thiocolchicine (20) (Fig. 6) demonstrate 
antileukemic activity by inhibiting the polymerization of 
tubulin, but both are highly toxic [24].  
Some pharmaceutical crops are managed for the produc-
tion of other categories of drugs. Artemisia annua L., com-
monly known as wormwood or qinghao, is an annual herba-
ceous species native to China and now cultivated throughout 
the world for production of the sesquiterpene lactone artem-
isinin (21) (Fig. 7) [7]. Artemisinin (21), used for semi-
synthesis of a common anti-malarial drug (Artemether), is 
also under investigation for cancer treatment. Other pharma-
ceutical crops are being cultivated for possible antiviral 
pharmaceuticals. For example, Syzygium claviflorum (Roxb.) 
Wall. ex A.M. Cowan & Cowan (Myrtaceae), from South-
eastern Asia and Australia, produces betulinic acid (22) (Fig. 
8), a lupane triterpenoid used in the semi-synthesis of di-
methyl succinyl betulinic acid (23) (Fig. 8) currently in anti-
AIDS clinical trials [24]. Lomatium suksdorfii J. M. Coult. & 
Rose (Apiaceae), from the Pacific northwest of the United 
States, is a major source of the anti-HIV (human immunode-
ficiency virus) coumarin suksdorfin (24) (Fig. 8), with semi-
synthetic analogs currently being tested in clinical trials. 
A number of pharmaceutical crops are being used to 
produce APIs for recently approved drugs for other diseases, 
such as Alzheimer’s, although some of the drugs are also 
obtained synthetically. Galanthus woronowii Losinsk. 
(Amaryllidaceae) and related genera, including Narcissus L., 
are sources of galantamine (Razadyne®/Razadyne® ER, 
formerly known as Reminyl) (25) (Fig. 8) [29]. This alkaloid 
is used for the treatment of mild to moderate Alzheimer’s 
disease. The leaves of Callistemon citrinus Stapf. and the 
seeds of Leptospermum scoparium Forst. & Forst. (two 
shrubby species of the Myrtaceae from Australia and New 
Zealand) are the major source of the allelopathic essential oil 
leptospermone (26) (Fig. 8); its analog mesotrione (27) (Fig. 
8) is used as a herbicide [30]. Recently, nitisinone (Orfadin®) 
(28) (Fig. 8), a derivative of mesotrione, was the first drug 
approved in Europe for the treatment of hereditary type 1 
tyrosinemia, a rare genetic metabolic disorder caused by a 
deficiency of the enzyme fumarylacetoacetate hydrolase 
(FAH) encoded by the FAH gene. This enzyme is involved 
in the metabolism of tyrosine [31].  
Opium (Papaver somniferum L., Papaveraceae) is well 
known as a natural source of important alkaloids such as 
morphine (29) (a potent narcotic analgesic drug), thebaine 
(30), codeine (31) (an analgesic antitussive drug), and  
 
Fig. (5). Harringtonine (17) and homoharringtonine (18), two natu-
ral alkaloids isolated from Cephalotaxus spp. (Cephalotaxus 
harringtonia cultivated in Texas, USA, photo by S.Y. Li). 
 
Fig. (6). Colchicine (19) and thiocolchicine (20), two natural alka-
loids isolated from Colchicum autumnale (Colchicum autumnale, 
photo by M.J. Balick). 
 
Fig. (4). Vinblastine (13) and vincristine (14), two natural vinca 
alkaloids isolated from Catharanthus roseus, and semi-synthetic 
anti-cancer drugs vinorelbine (navelvine) (15) and vindesine (eldis-
ine) (16) (Catharanthus roseus, photo by M.J. Balick). 
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Fig. (7). Artemisinin (21) isolated from Artemisia annua (Artemisia 
annua, photo by M.J. Balick). 
 
Fig. (8). Betulinic acid (22) isolated from Syzygium claviflorum and 
its semi-synthetic analog dimethyl succinyl betulinic acid (23), 
suksdorfin (24) isolated from Lomatium suksdorfii, Galantamine 
(25) from Galanthus woronowii, and leptospermone (26) from 
Callistemon citrinus and Leptospermum scoparium and its analogs 
mesotrione (27) and nitisinone (28). 
 
Fig. (9). Morphine (29), thebaine (30), codeine (31), oripavine (32), 
papaverine (33), noscapine (35), alkaloids isolated from Papaver 
somniferum and semisythetic apomorphine (34) (Papaver 
somniferum, photo by M.J. Balick).  
 
Fig. (10). Tropane alkaloids (−)-hyoscyamine (36) isolated from 
Atropa belladonna and semi-synthetic tiotropium (37) (Atropa 
belladonna, photo by M.J. Balick). 
oripavine (32) (Fig. 9). Papaverine (33) (Fig. 9), another 
opium poppy alkaloid, is a smooth muscle relaxant used 
principally for the relief of cerebral and peripheral ischemia 
associated with arterial spasm and myocardial ischemia 
complicated by arrhythmias [32]. Apomorphine (34) (Fig. 9), 
a semi-synthetic analog of morphine, was the first dopa-
minergic drug used to treat symptoms of Parkinson's disease 
[33]. Recently, noscapine (35) (Fig. 9), another important 
alkaloid found in opium poppy, has emerged as a promising 
lead for chemoprevention and treatment of cancers especially 
prostate cancer, and stroke [34]. Atropa belladonna L. (Fig. 
10), Hyoscyamus niger L., and Datura stramonium L. 
(Solanaceae) are sources of (−)-hyoscyamine (36) (Fig. 10) 
and atropine ((±)-hyoscyamine) which are used as anti-
muscarinic agents. Anti-muscarinic alkaloids and synthetics 
are used in the treatment of a number of digestive disorders. 
They are also used to control excess motor activity of the 
gastrointestinal tract and spasm of the urinary tract, to dilate 
the pupils during ophthalmological examination of the eyes 
and in cases of iritis, reduce respiratory secretions in 
anesthesia, and nasal and sinus secretions in common cold 
and allergy [32]. A semi-synthetic tropane analog, tiotropium 
(37) (Fig. 10), is used for treatment of bronchospasms 
associated with chronic obstructive pulmonary disease 
(COPD) [35]. Scopolamine or hyoscine (38), another tropane 
alkaloid found in Datura metel L. (Fig. 11), is used for 
nausea and vomiting associated with motion sickness and for 
preanesthetic sedation with analgesics [32]. Some other 
important APIs are alkaloids ephedrine (39) (Fig. 12) 
from Ephedra sinica Stapf (Ephedraceae), commonly known 
as ephedra or Ma Huang, a potent sympathomimetic bron-
chodilator for bronchial asthma and local treatment of nasal 
congestion [32, 36], physostigmine (40) (Fig. 12) used for 
glaucoma and Alzheimer's disease from Physostigma ve-
nenosum Balf. (Calabar bean or ordeal bean; Fabaceae) [32, 
37] and steroidal sapogenins diosgenin (41) (Fig. 12) from 
Dioscorea spp. (yams; Dioscoreaceae) and hecogenin (42) 
(Fig. 12) from Agava spp. (agaves; Agavaceae) for produc-
tion of steroidal drugs [38, 39]. 
Other pharmaceutical crops produce inactive or less ac-
tive pharmaceutical precursors used for synthesis of drugs. 
Liquidambar styraciflua L., known as sweetgum (Hama-
melidaceae), is one of the most common hardwood species 
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in the southeastern United States. Leaves of the tree contain 
up to 13.4% shikimic acid (43) (Fig. 13) [40]. Shikimic acid 
(43) has weak bioactivity, but is a precursor for the antiviral 
drug Tamiflu®. Commercial harvest and extraction methods 
for high concentrations of stable pure shikimic acid (43) 
from the leaves have been developed [40], making L. 
styraciflua a promising pharmaceutical crop.  
Pharmaceutical Crops for the Production of Large 
Therapeutic Molecules (LTMs) 
Pharmaceutical crops for LTMs (usually having a mo-
lecular weight of more than 10,000 Daltons) include (1) 
crops producing endogenous LTMs such as proteins and 
polysaccharides, and (2) GM or engineered crops for produc-
ing exotic proteins such as vaccines and antibodies.  
Plants produce a variety of bioactive proteins such as ri-
bosome-inactivating proteins (RIPs), defensins, cyclotides, 
and lectins [41]. Some of these proteins have shown promis-
ing anti-cancer, antiviral, and antifungal activities and im-
provement of immune function in humans [41, 42]. Some 
important examples include antifungal and antiviral panax-
agin from Asian ginseng (Panax ginseng C.A. Mey.; Arali-
aceae), quinqueginsin from North American P. quinquefolius 
L., trichosanthin and TAP 29 from Trichosanthes kirilowii 
Maxim. (Cucurbitaceae), Momordica Anti-HIV Protein 
(MAP30) from Momordica charantia L. (Cucurbitaceae), 
pokeweed antiviral protein (PAP) from leaves or seeds of 
Phytolacca americana L. (Phytolaccaceae), saporin found in 
seeds and leaves of Saponaria officinalis L. (Caryophyllaceae), 
gelonin from the seeds of Gelonium multiflorum A. Juss. 
(Euphorbiaceae), toxic ricin isolated from the castor bean 
(Ricinus communis L.; Euphorbiaceae), viscumin from Viscum 
album L. (Santalaceae), and abrin from seeds of Abrus 
precatorius L. (Fabaceae) [41-46]. Some proteolytic enzymes 
(proteases) isolated from plants are papain and chymopapain 
isolated from latex of papaya (Carica papaya L., Caricaceae), 
ficin from trunk latex of figs (Ficus carica L., F. glabrata 
Kunth; Moraceae), and bromelain from stem and fruits of 
pineapple (Ananas comosus (L.) Merr.; Bromeliaceae) [44].  
Transgenic plants have been used for the production of 
antibodies directed against dental caries, rheumatoid arthri-
tis, cholera, E. coli diarrhea, malaria, certain cancers, 
Norwalk virus, HIV, rhinovirus, influenza viruses, hepatitis 
B virus, and herpes simplex virus [47]. Protein antigens from 
various pathogens have been expressed in plants and used to 
produce immune responses resulting in protection against 
Vibrio cholerae, enterotoxigenic E. coli, hepatitis B virus, 
Norwalk virus, rabies virus, human cytomegalovirus, rotavi-
rus, and respiratory syncytial virus F [47]. In 2006, produc-
tion of the monoclonal antibody CB-Hep.1 (used in the 
manufacturing process for a Hepatitis B vaccine) in tobacco 
plants was approved in Cuba [48]. GM pharmaceutical crops 
could produce large quantities of drugs or vaccines at low 
costs. Production of therapeutic proteins by transgenic phar-
maceutical crops usually has shorter development cycles [5] 
and lower cost than those from cell culture systems [47]. 
Like mammalian cells, plant production systems have the 
advantage over microbial systems of being able to produce 
active forms of complex proteins with appropriate post-
translational modifications (e.g., glycosylation) [47]. Addi-
tionally, using pharmaceutical crops reduces the risk for un-
intentional transformation of viruses that infect humans as 
might occur when using mammalian cell systems.  
Pharmaceutical Crops for the Production of Standard-
ized Therapeutic Extracts (STEs) 
Crops in this category are usually used in traditional 
medicine in various countries. It is estimated that several 
thousand species are used for production of STEs in the 
 
Fig. (12). Ephedrine (39) isolated from Ephedra sinica, physostig-
mine (40) from Physostigma venenosum, diosgenin (41) from Dio-
scorea spp., and hecogenin (42) from Agava spp. 
 
Fig. (13). Shikimic acid (43) isolated from Liquidambar styraciflua 
(Liquidambar styraciflua in East Texas, USA, photos by S.Y. Li). 
 
Fig. (11). Scopolamine (38) isolated from Datura metel (Datura 
metel, photo by R. Howard). 
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world. Unlike STMs which are single molecular entities, 
STEs are a mixture of multiple active compound(s) extracted 
from pharmaceutical crops as standardized extracts. In this 
case the crops may be wild harvested, sometimes managed in 
local ecosystems, or cultivated in fields or environments 
such as agroforests. STEs can be mixtures extracted from 
one plant or from several to many different species. Many 
STEs are marketed and utilized in the same fashion as drugs 
in many parts of the world including China, Japan, India, 
Europe, and Africa. In the United States, STEs are usually 
classified as conventional foods and dietary supplements, 
depending on the specific claim as described in the Dietary 
Supplement Health and Education Act (DSHEA) of 1994. 
There has been an increasing interest in further development 
of STE drug products in recent years. In 2006, the FDA ap-
proved the first botanical drug Veregen® for the topical 
treatment of patients with perianal and genital condyloma 
[49]. The bioactivity of Veregen® is probably due to sine-
catechins, a mixture of catechins found in the partially puri-
fied fraction of the water extract of green tea leaves from 
Camellia sinensis (L.) Kuntze (Theaceae) (44-49) (Fig. 14), 
as well as other green tea components.  
Probably less than 1,000 species are cultivated, with most 
of the species being harvested in the wild. With increasing 
demands and decreasing resources in the wild, however, 
more and more species are cultivated as crops for production 
of STEs. Some well-known examples are Ginkgo biloba L. 
(Ginkgoaceae), echinacea (Echinacea angustifolia DC., E. 
purpurea (L.) Moench, E. palida (Nutt.) Nutt; Asteraceae), 
liquorice (Glycyrrhiza glabra L.; Fabaceae), St. John's Wort 
(Hypericum perforatum L.; Clusiaceae), ginseng (Panax 
ginseng C.A. Meyer, Araliaceae), American ginseng (Panax 
quinquefolius L., Araliaceae), pines (Pinus L., e.g., P. mari-
tima Miller., P. sylvestris L., P. radiata D. Don, P. massoni-
ana Lamb.; Pinaceae) (pine bark extract, containing proan-
thocyanidins), and Reishi (lingzhi) (Ganoderma tsugae, 
Ganodermataceae).  
STEs used as APIs could be a single class of active com-
pounds or synergistic mixtures of several classes of bioactive 
compounds. Cardiac glycosides such as oleandrin (50) and 
digitoxin (51) (Fig. 15) are compounds known to inhibit 
Na+/K+-ATPase activity and induce apoptosis [50, 51]. 
Members of this family of compounds have been in clinical 
use for many years for the treatment of heart failure and 
atrial arrhythmia [52]. Over the last ten years, emerging evi-
dence has suggested that cardiac glycosides or cardiac glyco-
side containing botanical extracts have great potential for 
managing malignant diseases [53-57]. For example, An-
virzel®, a hot water extract of oleander (Nerium oleander L.; 
Apocynaceae) (Fig. 15) contains oleandrin (50) as a principle 
cytotoxic component and has been evaluated in a Phase I 
clinical trial in the United States against refractory human 
cancers [50]. Additionally, the safety and anticancer re-
sponse of the supercritical CO2 extract of oleander is cur-
rently being evaluated in a Phase I trial at The University of 
Texas, M.D. Anderson Cancer Center. Ornamental oleander is 
now cultivated as a pharmaceutical crop in the United States.  
Some pharmaceutical crops are also cultivated for pro-
duction of both STEs and STMs, i.e., Pueraria lobata 
(Willd.) Ohwi (Fabaceae) for puerarin (52) (Fig. 16), 
 
Fig. (14). Catechins isolated from green tea leaves of Camellia 
sinensis: (−)-epigallocatechin gallate (EGCG) (44), (−)-epicatechin 
gallate (ECG) (45), (−)-epigallocatechin (EGC) (46), (−)-galloca- 
techin gallate (GCG) (47), (+)-epicatechin (EC) (48), and (−)-
catechin (49) (Camellia sinensis, photo by M.J. Balick). 
 
Fig. (15). Cardiac glycosides such as oleandrin (50) from Nerium 
oleander (photo by M.J. Balick) and digitoxin (51) from Digitalis 
purpursea. 
 
Fig. (16). Puerarin (52) isolated from Pueraria lobata (Pueraria 
lobata in Oxford, Mississippi, USA, photos by S.Y. Li). 
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Lithospermum erythrorhizon Sieb. & Zucc. (Boraginaceae) 
for shikinon (53) (Fig. 17), Salvia miltiorhiza Bunge (La-
miaceae) for tanshinone I (54), tanshinone IIA (55), salvi-
anolic acid B (lithospermic acid B) (56), rosmarinic acid 
(57), cryptotanshinone (58), and neotanshinlactone (59) (Fig. 
18), and Glycyrrhiza glabra L. for glycyrrhizin (60) (Fig. 
19). Salvia miltiorhiza, one of the most popular plants used 
in traditional Chinese medicine, has been cultivated as a 
pharmaceutical crop in many Asian countries for the treat-
ment of coronary heart disease, cerebrovascular disease, and 
inflammation [58, 59]. Although numerous varieties of S. 
miltiorhiza have been grown since the 1960s, a high-yielding 
cultivar is not yet available. The quality of APIs in cultivated 
S. miltiorhiza is much lower than that in wild populations 
[60]. Although the harvested biomass rhizome production 
was increased significantly by applications of nitrogen fertil-
izers, the low and unstable yield of APIs has been a major 
problem with this species [58]. The medicinal potential of 
several other species of Salvia has been investigated [61, 62]. 
 
Fig. (19). Glycyrrhizin (60) isolated from Glycyrrhiza glabra (photo 
by M.J. Balick). 
HOW PHARMACEUTICAL CROPS RELATE TO 
OTHER PLANTS AND CROPS 
Pharmaceutical crops are a class of crops incorporating 
agriculture with medicine. Their relationships to medicinal 
plants, crops, medicinal crops, and traditional food crops are 
summarized in the Fig. 20.  
Fig. (20). Relationships of pharmaceutical crops (PC) to crops, 
medicinal plants, medicinal crops (MC), and traditional food crops 
(TFC). 
Relationship to Medicinal Plants  
There are over 70,000 plant species thought to be of me-
dicinal value in the world [63]. Most of the medicinal plants 
in the world are still harvested in the wild and have not been 
developed as crops. In China, for example, there are ap-
proximately 31,000 plant species [64]. A total of 11,146 
plant species have been recorded in Chinese herbal or medi-
cal literature according to a national survey conducted in 
1995 [65]. Only 10% (1,200 species) are marketed as com-
mercial medicines [66], of which 300 species are often culti-
vated as crops [58]. This trend is consistent with the use of 
the angiosperms as food; while over 3,000 are known to be 
used as foods only about 150 are in the economic system and 
 
Fig. (17). Shikinon (53) isolated from Lithospermum erythrorhizon 
(photo by S.L. Chen). 
 
Fig. (18). Tanshinone I (54), tanshinone IIA (55), salvianolic acid 
B (lithospermic acid B) (56), rosmarinic acid (57), cryptotanshi-
none (58), and neotanshinlactone (59) isolated from Salvia miltio-
rhiza (photo by Y.L. Lin). 
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of those only a handful are major crops with global nutri-
tional significance.  
Most of the natural products in clinical use today were 
discovered through a routine examination of terrestrial plants 
and microorganisms [67]. Most pharmaceutical crops have 
their origins in previously known medicinal plants. How-
ever, some pharmaceutical crops emerged from the discov-
ery, through established bioactivity-guided screens, of mole-
cules in plants that have not previously been used in tradi-
tional medicine or considered as medicinal plants. Excellent 
examples of this include taxanes from Taxus and CPT from 
Camptotheca. 
Relationship to Medicinal Crops 
Many medicinal crops, originally cultivated for use in 
traditional medicine are now managed as pharmaceutical 
crops for STEs. For example, most of the 300 species com-
monly cultivated crops are currently also used for production 
of STEs in addition to their traditional uses. Other medicinal 
crops which are not used pharmaceutically, but which have a 
long history in folk medicine (herbal preparations) are only 
cultivated locally. These traditional medicinal crops could 
have potential as pharmaceutical crops in the future. As dis-
cussed above, some medicinal crops such as Pueraria lo-
bata, Lithospermum erythrorhizon, Salvia miltiorhiza, and 
Glycyrrhiza glabra have been long cultivated as pharmaceu-
tical crops for production of both STEs and STMs.  
There is no clear definition for medicinal crops, the only 
criterion being that this class of cultivated species has some 
form of “traditional medicinal use”. However, not all phar-
maceutical crops have medicinal uses. As mentioned above, 
some food, vegetable, and spice crops are used for pharma-
ceutical purposes even though they are not typical medicinal 
crops. Likewise, some pharmaceutical crops are used as 
source of excipients (inert molecules) used in drug formula-
tions as binders, fillers, disintegrants, emulsifying agents 
(e.g., gum Arabic and gum tragacanth). 
Relationship to Traditional Food Crops  
Some traditional food and vegetable crops are genetically 
modified or engineered to produce therapeutic proteins and 
thus are managed as pharmaceutical crops. In many cultures, 
medicinal diets have a long history together with cereals, 
vegetables, fruits, nuts, and spices which are used both as 
food and medicine. Over 2,000 plant species have been used 
as medicinal diets in China since the Tang Dynasty [68]. In 
the last several decades, standardized extracts or pure iso-
lates from some traditional food crops have been developed 
as promising chemopreventive agents and even medicines 
[68].  
Some traditional food crops have been developed as nu-
tritional crops which are defined as sources for extraction or 
preparation of nutritional substances [69]. Nutritional crops 
can be also considered as pharmaceutical crops when some 
of their substances possess therapeutic properties. Grape 
(Vitis L.; Vitaceae) is a common nutritional crop. A number 
of studies suggest that grape seed extract (GSE, containing 
antioxidant oligomeric proanthocyanidins or OPCs) is useful 
for a variety of heart diseases and cancers. Many pharmaceu-
tical products containing OPCs are available in the global 
market. Similarly, blueberries (Vaccinium L.; Ericaceae) are 
mainly cultivated for their nutritious berries, but the leaves 
are now also used for producing medicinal extracts [70]. 
Citrus fruits (Citrus L.,; Rutaceae) contain a variety of phy-
tochemicals including flavonoids, limonoids, carotinoids, 
and vitamin C, and serve as a source of folic acid, high qual-
ity soluble fiber, and potassium [71]. Recent identification of 
the antiproliferative activity of limonoids (61) (Fig. 21) from 
citrus against various human tumors [71-73] may lead to its 
development as a pharmaceutical crop. 
 
Fig. (21). Limonoids (limonin (61)) isolated from citrus (Citrus) 
(photos by S.Y. Li). 
Celery (Apium graveolens L. var. dulce DC.; Apiaceae) 
is an important vegetable crop. Apigenin (62) (Fig. 22), a 
flavone isolated from celery which has been used to dye wool, 
has been shown to possess remarkable anti-inflammatory, 
antioxidant and anti-carcinogenic properties [74]. The cancer 
chemo-preventive effects of apigenin (62) have recently been 
reported [74].  
 
Fig. (22). Apigenin (62) isolated from celery (Apium graveolens) 
(photo by S.Y. Li). 
Spice crops may also be cultivated as pharmaceutical 
crops. Tumeric (Curcuma longa L.; Zingiberaceae) (Fig. 23) 
and star anise (Illicium verum Hook. f.; Illiciaceae) are two 
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common spices in Asia, but they are also cultivated for pro-
duction of the pharmaceutical ingredients curcuminoids and 
shikimic acid (43), respectively. Curcuminoids, including 
curcumin (63), demethoxycurcumin (64), and bisde-
methoxycurcumin (65) (Fig. 23) have demonstrated anti-
inflammatory and anticancer activity and promising potential 
in cancer prevention [75-77]. Aromatic plants not only serve 
as condiments and as important resources in the perfume and 
cosmetic industries, but have gained wide popularity now in 
aromatherapy [78, 79]. 
Relationship to Invasive Species 
Some well-known invasive species in the United States 
such as kudzu or ge gen (Pueraria lobata), Japanese honey-
suckle (Lonicera japonica Thunb.; Caprifoliaceae), and 
Japanese climbing fern (Lygodium japonicum (Thunb.) 
Sweet; Schizaeaceae) are currently managed as pharmaceuti-
cal crops in China and Japan. Kudzu is an invasive weed in 
the southeastern United States (Fig. 16) which can com-
pletely replace existing vegetation. Eradication by herbicides 
can cost over $200 per acre for five years and thus is often 
commercially unfeasible [80]. In its native China, the vine is 
managed as a pharmaceutical crop to prepare extracts or iso-
late puerarin (52), or as a food crop. Puerarin (52) can induce 
angiogenesis in the myocardium and has been used to treat 
patients with cardiovascular diseases [81]. 
Each year, 3 million acres of land in the United States are 
taken over by invasive weeds. The spread of invasive plants 
is ranked second, behind habitat loss, as the greatest threat to 
biological diversity and ecosystem function in the United 
States. Controlling invasive species and the associated eco-
nomic and environmental damages amounts to more than 
$138 billion per year [82]. More than $500 million is spent 
on residential exotic weed control and an additional $1 bil-
lion is invested in non-indigenous weed control on golf 
courses [82]. Efforts to control invasive species have been 
focused on “negative actions” such as herbicide or mechani-
cal applications or biological control. A focus on utilization 
(positive actions such as identification of useful compounds 
in existing invasive species and subsequent development of 
these species as specialty or pharmaceutical crops valuable 
enough to stimulate removal/harvest and utilization—not 
replanting) rather than on elimination should be investigated 
as a possible approach to this problem in the United States 
and globally. 
WHY PHARMACEUTICAL CROPS? 
Plants as a Major Source of Drug Discovery 
Plants have formed the basis for traditional medicine sys-
tems which have been used for thousands of years in China, 
India, and Egypt and later by the Greeks and Arabs. Botani-
cal medicines still contribute to improving public health of 
the majority of the world’s population [63, 83]. Plants have 
also proven to be a major source for the discovery of modern 
drugs, particularly in the cancer field [84]. Of 155 small 
molecules developed as anti-cancer drugs worldwide from 
the 1940s to the present time, 72.9% are naturally-inspired, 
with 47% being either the natural products or semi-synthetic 
derivatives [85]. Many well-known anti-cancer drugs are of 
plant origin, e.g., CPTs (3-4), taxanes (5-7), podophyllins 
(10-12), and vinca alkaloids (13-16) [67, 86]. Several ex-
perimental plant-based drugs have also shown promising 
potential: homoharringtonine (18) (alkaloid from Cephalo-
taxus harringtonia) for leukemia; 4-ipomeanol (a pneumo-
toxic analog of furan isolated from Ipomoea batatas (L.) 
Poir.) for lung cancer; elliptinium (a semi-synthetic analog 
of ellipticine from Bleekeria vitiensis (Markgr.) A.C. Smith) 
for advanced breast cancer; and flavopiridol (a synthetic fla-
vone derived from alkaloid rohitukine isolated from Amoora 
rohituka (Roxb.) Wight & Arn. and Dysoxylum binectarif-
erum Hook. F. ex Bedd.) for colorectal cancer [87]. As Drs. 
Wall and Wani stated, “undoubtedly, there are other highly 
active natural products from plant, marine, and fungal 
sources as yet unknown which, when discovered, will have 
therapeutic utility. Cancer is not one, but several hundred 
diseases and will require many different types of agents” 
[18]. 
Plants are the obvious choice for future research of drug 
development because they contain an almost infinite variety 
of novel molecules [88]. Many compounds have very com-
plex structures that are too difficult and expensive to 
synthesize on an industrial scale. The global market for bo-
tanical and plant-derived drugs is expected to increase from 
$19.5 billion in 2008 to $32.9 billion in 2013 [89]. However, 
insufficient supply of source material has been one of the 
major problems for bulk production of plant-based pharma-
ceuticals [90].  
Pharmaceutical Crops as a Solution to Secure Sustain-
able Supplies of Quality Medicine 
Of the world’s total flora of higher plants (estimated be-
tween 215,000 and 500,000 species), only 6% have been 
screened for biological activity and 15% evaluated phyto-
chemically [91, 92]. Actually, far fewer species have been 
thoroughly screened or chemically investigated. Plants have 
been proven and will continue to provide novel leads for 
drug development [84, 90, 93-97]. Due to habitat destruc-
tion, overharvest, lack of sustainable utilization and conser-
vation programs, however, species diversity and genetic di-
versity of medicinal plants are continuously under the threat 
of extinction. It has been estimated that 22-46% of the 
world’s total plant species are endangered [98].  
 
Fig. (23). Curcuminoids (curcumin (63), demethoxycurcumin (64), 
and bisdemethoxycurcumin (65)) isolated from tumeric (Curcuma 
longa) (photos by S.Y. Li and M.J. Balick). 
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Many medicinal plants are being destroyed at an un-
precedented rate and are threatened with extinction [63]. As 
Balick and Mendelsohn pointed out, the value of sustainably 
harvesting locally used medicinal plants in a forest plot in 
Belize far exceeded the use of that same land for agriculture 
[99]. The disappearance of medicinal plants, in addition to 
reducing the access of a local population to primary health 
care remedies, also threatens future efforts in drug discovery. 
At present, of the 70,000 species of medicinal plants in the 
world still primarily harvested in the wild, most have not 
been cultivated as crops. For example, of the 3,000 species 
of medicinal plants being traded in the world, 70-80% origi-
nate from wild-collections [100, 101], and only 900 have 
commercial cultivation underway or in development [102]. 
Some 15,000 medicinal plant species may be threatened with 
extinction [63].  
Over-harvesting and loss of habitat often directly threaten 
medicinal plants. Current supplies of many critical pharma-
ceuticals having global demands still rely on wild collection. 
For example, Taxus tree species in North America and China 
were harvested for bark and needles to produce the cancer 
drugs paclitaxel (5) and docetaxel (6) and they are now in 
endangered status. Cultivation of Taxus species has now 
become essential to supplying these compounds. Hoodia 
gordonii Sweet ex Decne (Asclepiadaceae) in Southern Af-
rica and Namibia and some other species of the genus are 
sources of weight loss drugs [103]. Hoodia gordonii is now 
included in the Convention on the International Trade in 
Endangered Species of Wild Fauna and Flora (CITES) Ap-
pendix II list in an attempt to control over-harvesting [103], 
and again, cultivation of Hoodia is now underway.  
Over 2,000 medicinal and aromatic plants are traded 
commercially in Europe, and it is estimated that around 150 
plant species are threatened in at least one European country 
by this trade [104]. Colchicum autumnale L. (Colchicaceae) 
used for gout is an example. Arnica montana Lam. (As-
teraceae) and Gentiana lutea L. (Gentiaceae) are harvested 
throughout Europe (especially in Bulgaria and Romania) but 
are becoming scarce.  
In China, of 354 species on the Chinese Endangered 
Plant Species List, 168 species are medicinal plants [105]. 
Over 30 species often used in Chinese medicine are endan-
gered and in short supply, e.g., ginseng, Glycyrrhiza glabra, 
Angelica sinensis (Oliv.) Diels (Apiaceae), Ligusticum 
chuanxiong S. H. Qiu, Y. Q. Zeng, K. Y. Pan, Y. C. Tang & 
J.M. Xu (Apiaceae), Dysosma versipellis (Hance) M. Cheng 
ex T. S. Ying (Berberidaceae), Changium smyrnioides H. 
Woff (Apiaceae), Actinidia macrosperma C. F. Liang (Acti-
nidiaceae), as well as three well-known woody medicinal 
plants the bark of which is used namely, Magnolia officinalis 
Rehder & E. H. Wilson (Magnoliaceae), Phellodendron 
amurense Rupr. (Rutaceae), and Eucommia ulmoides Oliv. 
(Eucommiaceae) [105, 106].  
Extinction of wild plants will not only thwart the discov-
ery of new drugs, but also limit the sustainable supply of 
quality plant-based pharmaceuticals. In China, the decreas-
ing genetic pool of wild plants has resulted in quality prob-
lems with products from over 100 species frequently used 
for medicine [105]. Furthermore, indigenous knowledge of 
the value of many medicinal plants is being lost very 
quickly, although the vast majority of the earth’s plants have 
yet to be thoroughly analyzed for their potential to improve 
healthcare [103]. Ethnobotanical research has an important 
role to play in drug discovery through establishing an inven-
tory and then helping local people to conserve this aspect of 
traditional knowledge [107-109]. 
Although the disappearance of many medicinal plants is 
primarily the result of over-harvesting and loss of habitat, the 
lack of sustainable agriculture systems and conservation 
practices designed to maintain both biological and cultural 
diversity threatens the future use of medicinal plants and 
thus drug discovery programs. Current efforts such as in situ 
and ex situ conservation strategies which include cultivation 
in botanical gardens will preserve some endangered medici-
nal plant germplasm, but this should also include under-
standing and preservation of the knowledge of their value. 
Development and cultivation of pharmaceutical crops, how-
ever, will not only conserve endangered medicinal biodiver-
sity, but will also provide sustainable production of thera-
peutic molecules. In addition, pharmaceutical crop research 
will help to conserve and utilize decreasing biological and 
cultural diversity and thus enhance the potential for drug 
discovery. 
Development of pharmaceutical crops will secure sup-
plies of vital medicines particularly important in emergent 
cases such as threat of pandemic infectious diseases. Some 
countries must currently import APIs to produce antiviral 
and anti-cancer drugs, and foreign supplies may be uncer-
tain. Cultivation of newly emerging pharmaceutical crops in 
these locations may open the door to less expensive and 
more readily available drugs, and revitalize rural economies 
by establishing high-value crops. 
Problems and Challenges with Pharmaceutical Crop De-
velopment 
At present, when compared to research and development 
of food and fiber crops, similar programs to address pharma-
ceutical crops for therapeutic are very limited. Unlike tradi-
tional food crops and yet-to-be-developed energy crops for 
biomass, research in pharmaceutical crops focuses on the 
maximization and sustainable production of target chemical 
compound(s) from the plants. This involves the integration 
of techniques used in traditional crops including plant breed-
ing, physiology and ecology, coupled with research in the 
fields of pharmacognosy, pharmacology, and eventually 
clinical studies. Integration of these different areas with in-
terdisciplinary teams of scientists working towards a com-
mon goal appears to be the key to success.  
The discoveries of CPT (1) and Taxol® (5) by Drs. Wall 
and Wani “firmly established the fact that the close coopera-
tion between chemists and botanists was required for a suc-
cessful natural products program” [18]. In search of novel 
bioactive natural products, chemists commonly start with 
dried plant parts (or tissues) provided by botanists and may 
never see the living plants. In contrast, botanists and plant 
physiologists are primarily focused on the content variations 
or biosynthesis of target compounds in intact plants or cell 
culture systems. Both chemists and biologists realize that 
inducible biosynthesis of target compounds will require ex-
tensive efforts in in vitro production and microbial biotrans-
formation of these compounds. However, management of 
intact plant systems as reactors for derivatization of novel 
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bioactive agents has never been seriously addressed. As a 
matter of fact, important secondary metabolites such as mor-
phine are produced in significant amounts only in the intact 
plant, with the biosynthetic pathway being repressed in cell 
culture. Pharmaceutical crops are platforms for biologists, 
chemists, pharmacists, health professionals and clinicians to 
collaborate closely in making new drug discoveries in all 
disease areas. Several problems have tempered both indus-
trial and academic enthusiasm for research and funding in 
pharmaceutical crops as a production system, particularly for 
the production of STMs in great global demand. In addition 
to decreasing genetic diversity in nature and environmental 
concerns (i.e., endangered species), factors including slow 
plant growth, long harvest cycle, and low and unstable yields 
of desired compounds in wild plants have been major prob-
lems in the large scale management of crops and production 
of the pharmaceuticals. Often, the yield and quality of phar-
maceuticals from cultivated plants is not equivalent to those 
in the wild, even in common crops with a long cultivation 
history, such as Salvia miltiorhiza [58, 60]. Therefore, prior-
ity research in both intact plant and cell culture (when feasi-
ble) should be carried out to select and develop high and 
stable yielding varieties or strains having the desired target 
compound(s).  
Future pharmaceutical crop research efforts should also 
emphasize the strategies to enhance the yield of therapeutic 
molecules or precursors in sustainable crop production sys-
tems. To obtain a diversity of bioactive analogs, methods 
need to be developed to increase derivatization of the desired 
compounds in intact plants or in vitro systems, in addition to 
exploring microbial biotransformation. In some cases, STMs 
or precursors accumulate in glandular trichomes of plants. 
The shape and size of glandular trichomes from different 
species within a genus may vary considerably but are highly 
heritable [14, 16]. Induction of the production of glandular 
trichome in plants could significantly increase the yield of 
the target compounds. In the 1990s, the “Trichome Man-
agement” technique was developed to increase both biomass 
of leaves and stems and the density of glandular trichomes 
on leaves and stems by controlling auxin levels [14, 16] (Fig. 
23 to Fig. 24). This method induced production of glandular 
trichomes and thus increased alkaloid CPT yield by 16 to 20-
fold, and derivatization of CPT in Camptotheca [14, 16, 110, 
111]. The alkaloidal induction by auxin reduction in Camp-
totheca consists of two steps: an emergent response to trans-
locate alkaloids from old to young tissues and a systematic 
response to increase alkaloidal contents in the entire plant 
[16]. Recently, trichome density was used as a trait to 
quickly screen and develop high-yielding varieties of Artem-
isia annua for sesquiterpenoid artemisinin yield [112]. Al-
though both trichome density and secondary metabolites 
may be inducible by auxin-reducing pruning [16, 40, 110], 
the induction mechanism remains elusive. Existing hypothe-
ses attempting to explain the increase in secondary metabo-
lite concentration after damage are conflicting (supply-side 
vs. demand-side); but both emphasize the defense function 
of secondary metabolites, particularly of phytoalexins [113, 
114]. However, the role of defense in induced biosynthesis 
of toxic compounds in plants needs further investigations. 
The chemicals produced by Taxus spp., Artemisia annua, 
and Camptotheca spp. are among the most extensively in-
vestigated. There is no information on whether protection 
from herbivores or pathogens occurs in Taxus or Artemisia 
[115]. In Camptotheca, elevated toxic CPTs did not increase 
the antifungal activity of the plants but actually induced 
plant endogenous autotoxicity [110]. Thus, a chemical de-
fense role should not be overemphasized in the induced bio-
synthesis of some toxic secondary metabolites. Another in-
teresting topic worthy of investigation is the cyclical nature 
of plant chemical levels within individuals of the same spe-
cies. For example, in Hypericum perforatum, levels of hy-
pericin and pseudohypericin were found to vary between 100 
ppm and 5,000 ppm from winter to summer [116].  
Selection of optimum or suitable zones for crop cultiva-
tion is important to the development of high-yield and sus-
tainable production systems, particularly for crops with long 
 
Fig. (24). “Trichome Management” method to induce biosynthesis and derivatization of camptothecin (CPT) in Camptotheca acuminata: 
glandular trichomes on the leaf and stem surfaces as accumulation sites of CPTs are management target in selection and cultivation of high-
yielding variety [14, 16, 103] (photos by S.Y. Li and K. Northrup). 
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harvest cycles. The process involves analysis of multiple 
factors in ecology, climatology, geology, biology, and chem-
istry. Recently, some GIS (Geographic Information System)-
based models for adaptability analysis were established 
[117]. Some regional zoning efforts have also been made 
with several common traditional medicinal crops in China 
[117]. In non-native ranges, conducting field trials over large 
regions are time and cost prohibitive and could limit cultiva-
tion of crops in new areas. 
The difficulty in isolating and characterizing complex 
natural products is becoming less of a problem as HPLC-MS 
and HPLC-NMR are more routinely used and new methods 
for isolation and structural elucidation continue to be devel-
oped [90]. However, purification of some desired com-
pounds from pharmaceutical crops, and particularly the 
elimination or reduction of interfering compounds in plants 
continues to be a major challenge in extraction. Effective 
isolation of desired compounds in intact plant systems needs 
to be further investigated. 
In recent decades there have been great efforts and sig-
nificant progress in exploring other options to produce thera-
peutic compounds. Although chemical synthesis is a com-
mercially feasible option for those compounds with rela-
tively simple structures such as aspirin and ephedrine, it is 
not an appropriate strategy for complex structures [118-120]. 
Semi-synthesis from more abundant natural precursors is 
often necessary to prepare structurally complex drugs, e.g., 
semi-synthesis of taxane-based drugs (5-7) from natural bac-
catins isolated from Taxus spp. [22, 23]; also semi-synthesis 
is often used to convert toxic natural products to derivatives 
having more acceptable pharmacological properties, e.g., the 
conversion of CPT (1) to topotecan (3) and irinotecan (4). 
Metabolic engineering of target secondary metabolites in 
plants is feasible, but requires knowledge of the biosynthetic 
pathways [121]. The secondary metabolic pathways of only 
a few plants have been studied in detail which limits pro-
gress in this area [119, 121]. Catharanthus roseus and Rau-
volfia serpentina Benth. ex Kurz (Apocynaceae) have been 
used as model systems for the investigation of monoterpene 
indole alkaloid production by in vitro culture techniques, 
particularly cell suspension cultures, since the early 1980s 
[119]. However, C. roseus and R. serpentina crops are still 
the only viable commercial source of the anti-cancer vinca 
alkaloids and anti-hypertensive Rauwolfia alkaloids [119, 
122, 123]. Successful examples of secondary metabolite 
production by plant cell suspension cultures include the anti-
cancer paclitaxel (5) from Taxus spp.; the anti-cholinergic 
scopolamine (38) from Duboisia spp. (Solanaceae); the anti-
biotic berberine from Coptis japonica Makino (Ranuncu-
laceae); the anti-inflammatory rosmarinic acid (57) from 
Coleus blumei Benth. (Lamiaceae); and the anti-inflammatory 
and antiviral shikonin (53) from Lithospermum erythrorhizon 
Siebold et Zucc. (Boraginaceae) [124]. Other options includ-
ing expression of plant pathways in microbial systems have 
been explored. The commercial potential of hairy root cul-
tures for production of plant-derived pharmaceuticals has 
been limited primarily due to challenges in cultivating hairy 
roots in a large scale system [120]. Research and develop-
ment in these fields will definitely enhance the pivotal role 
of pharmaceutical crops. In general, however, the use of in-
tact plant systems means lower cost of production and easier 
expansion for large-volume production [47]. Instead of a 
large capital investment in cell culture facilities, plant pro-
duction systems can be expanded simply by growing and 
harvesting additional plants.  
Conservation biologists and ecologists have raised con-
cerns about the biosafety and environmental impacts of GM 
pharmaceutical crops. The potential environmental impacts 
(e.g., gene flow between cultivated crops and their wild rela-
tives) of genetically engineered crops for pharmaceuticals 
need constant analysis and evaluation. However, the use of 
biotechnology in pharmaceutical crops and conservation of 
biodiversity are not mutually exclusive.  
Another issue is reciprocity to indigenous cultures and 
people that contributed knowledge and resources for devel-
opment of pharmaceutical crops and their products. To en-
sure that more equitable benefits accrue from the use of bio-
logical resources, the United Nations Convention on Bio-
logical Diversity (CBD) was drafted during the Earth Sum-
mit in Rio de Janiero in 1992 [125]. Since then, there has 
been an increasing awareness in developing countries of the 
potential value of their indigenous genetic resources [126]. 
In fact, governments and conservation biologists have made 
extensive efforts to ensure the sustainable use of biodiversity 
and benefit sharing from revenues generated from plants 
originally used by indigenous and local people in traditional 
medicine. Shaman Pharmaceuticals developed a model for 
the pharmaceutical industry to have multi-stage benefit shar-
ing with governments and traditional cultures in its drug dis-
covery from Amazonian plants [125, 127], and the National 
Cancer Institute produced a series of agreements to address 
this issue that are also used as models by others [126]. Re-
cently, some have argued that all nature-based patents should 
acknowledge evolution by natural selection as a ‘co-
inventor’ and should allocate 1% of patent ownership to-
wards efforts to conserve biodiversity [128].  
CONCLUSIONS  
Pharmaceutical crops can be defined as cultivated species 
that are used for the extraction or preparation of therapeutic 
substances such as active pharmaceutical ingredients (APIs), 
excipients used in pharmaceutical formulations, vaccines and 
antibodies, as well as other therapeutic proteins. Basically, 
there are three types of pharmaceutical crops: crops for the 
production of small therapeutic molecules (STMs), large 
therapeutic molecules (LTMs), and standardized therapeutic 
extracts (STEs). This review focuses on examples of terres-
trial plants although pharmaceutical crops could be either 
terrestrial or aquatic species. Pharmaceutical crops are a rela-
tively new class of crops having close relationships with 
medicinal plants, medicinal crops, and traditional crops. Un-
like traditional food crops and yet-to-be-developed energy 
crops for production of biomass, research in pharmaceutical 
crops focuses on the maximization and sustainable produc-
tion of target chemical compound(s) from the plants. This 
involves the integration of techniques used in traditional 
crops including plant breeding, physiology and ecology, 
coupled with research in the fields of pharmacognosy, phar-
macology, and eventually clinical studies. Successful devel-
opment of pharmaceutical crops requires extensive joint ef-
forts of scientists in these different fields. Research in the 
area of invasive species has been focused on elimination, but 
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the potential for the development of some species as phar-
maceutical crops needs to be exploited. Future development 
of pharmaceutical crops should emphasize strategies to en-
hance the yield and derivatization of therapeutic molecules 
or precursors in sustainable crop production systems, includ-
ing development of high-yielding cultivars, cultivation tech-
nology for induced production of desired compounds, and 
effective and environmental-friendly extraction methods. In 
addition, biosafety, environmental impacts, and benefit shar-
ing should be addressed in the research and development of 
pharmaceutical crops. 
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ABBREVIATIONS 
API = Active pharmaceutical ingredient 
CBD = The United Nations Convention on Biological 
Diversity 
CITES = Convention on the International Trade in En-
dangered Species of Wild Fauna and Flora 
CPT = Camptothecin 
COPD = Chronic obstructive pulmonary disease 
10-DAB = 10-deacetylbaccatin III 
DSHEA = Dietary Supplement Health and Education Act 
FAH = Fumarylacetoacetate hydrolase 
FDA = The United States Food and Drug Administra-
tion 
GIS = Geographic information system 
GM = Genetically modified 
GSE = Grape seed extract 
HCPT = 10-hydroxycamptothecin 
HIV = Human immunodeficiency virus 
LTM = Large therapeutic molecule 
MAP30 = Momordica anti-HIV protein 
OPC = Oligomeric proanthocyanidin 
PAP = Pokeweed antiviral protein 
RIP = Ribosome-inactivating protein 
STE = Standardized therapeutic extract 
STM = Small therapeutic molecule 
TOPI = DNA topoisomerase I 
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